PROCEPT BioRobotics (PRCT): Earnings Growth Forecasts Challenge Long-Standing Concerns Over Ongoing Losses

PROCEPT BioRobotics (PRCT) remains unprofitable, with net losses having grown at an annualized rate of 14.1% per year over the last five years and a negative profit margin. However, analysts are looking ahead, forecasting earnings growth of 71.13% per year and revenue increases of 18.8% annually. Both figures are well above the broader US market’s 10.5% projected growth. With profitability anticipated within the next three years, investors are weighing the promise of future gains against past challenges.

See our full analysis for PROCEPT BioRobotics.

Next, we’ll break down these results against the most widely followed narratives about the company to see which perspectives hold up and which might get upended by the latest numbers.

See what the community is saying about PROCEPT BioRobotics

Margin Expansion on the Horizon

• Analysts anticipate that PROCEPT BioRobotics' profit margin, currently at -30.6%, could improve to match the US Medical Equipment industry average of 12.5% within the next three years.
• According to the analysts' consensus view, substantial margin improvement is seen as achievable largely because of recently expanded reimbursement and increased Aquablation adoption. These factors are expected to support sustained growth and eventual margin expansion.
  • Consensus narrative notes that broader clinical adoption and a permanent CPT code could boost procedure volumes, accelerating not just revenue but also margin improvements over time.
  • Analysts expect this margin shift to underpin durable earnings as procedure growth supports ongoing operating leverage.

Consensus sees accelerated margin growth as Aquablation adoption broadens and reimbursement tailwinds increase. Read why this could be pivotal for the narrative. 📊 Read the full PROCEPT BioRobotics Consensus Narrative.

Product Reliance Magnifies Growth Risks

• PROCEPT’s heavy dependency on its core Aquablation/HYDROS system increases its vulnerability if a competitor introduces a more advanced or cost-effective product, potentially threatening future diversification.
• Consensus narrative highlights the risk that, despite current positive trends, long-term earnings stability is threatened by operating losses, supply chain vulnerabilities, and regulatory pressures.
  • Bears argue that with only a 20% procedural share in the hospital market and a limited installed base, PROCEPT faces hurdles in converting new accounts to consistent, high-volume usage.
  • Regulatory or reimbursement shifts, including recent cuts to urology physician fees, could slow procedure adoption and alter growth trajectories.

Valuation Split: Discount to Peers, Premium to Sector

• The company trades at a price-to-sales ratio of 6.4x, lower than close peers (6.8x) but well above the US medical equipment industry average of 2.9x. Meanwhile, the current share price of $31.61 sits below the analyst target of $56.30, leaving significant upside if consensus forecasts hold true.
• Consensus narrative sees this valuation as a mixed signal; on one hand, the lower peer multiple presents a potential bargain if revenue and margin expansion targets are met. On the other, the premium to the sector average and reliance on strong future growth rates means investors should actively test these assumptions against real-world progress.
  • If margins and revenue reach targets, today’s price could offer strong value. However, any slip in expansion or unforeseen risk would quickly erase the perceived discount.
  • With no identified near-term risks in the data, investors are left to weigh the sector premium against growth ambitions and the possibility of achieving industry-level profitability.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for PROCEPT BioRobotics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have your own take on the data? Shape your perspective into a personal narrative in just a few minutes and Do it your way

A good starting point is our analysis highlighting 1 key reward investors are optimistic about regarding PROCEPT BioRobotics.

See What Else Is Out There

While PROCEPT BioRobotics shows ambitious growth forecasts, its dependence on a single product and ongoing losses highlight risks to consistent earnings and stability.

If you want to prioritize companies delivering proven financial strength and reliable foundations, start your search with solid balance sheet and fundamentals stocks screener (1974 results) built to withstand uncertainty and protect your investments.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com